A Phase 1, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenously Administered AVLX-144
Latest Information Update: 24 Jul 2023
At a glance
- Drugs AVLX-144 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Avilex Pharma
- 18 Jul 2023 Status changed from recruiting to completed.
- 05 Jan 2021 New trial record